84 reports of this reaction
1.3% of all CALCIUM POLYCARBOPHIL reports
#20 most reported adverse reaction
COGNITIVE DISORDER is the #20 most commonly reported adverse reaction for CALCIUM POLYCARBOPHIL, manufactured by Aurobindo Pharma Limited. There are 84 FDA adverse event reports linking CALCIUM POLYCARBOPHIL to COGNITIVE DISORDER. This represents approximately 1.3% of all 6,699 adverse event reports for this drug.
Patients taking CALCIUM POLYCARBOPHIL who experience cognitive disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COGNITIVE DISORDER is a less commonly reported adverse event for CALCIUM POLYCARBOPHIL, but still significant enough to appear in the safety profile.
In addition to cognitive disorder, the following adverse reactions have been reported for CALCIUM POLYCARBOPHIL:
The following drugs have also been linked to cognitive disorder in FDA adverse event reports:
COGNITIVE DISORDER has been reported as an adverse event in 84 FDA reports for CALCIUM POLYCARBOPHIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
COGNITIVE DISORDER accounts for approximately 1.3% of all adverse event reports for CALCIUM POLYCARBOPHIL, making it a notable side effect.
If you experience cognitive disorder while taking CALCIUM POLYCARBOPHIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.